Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.62 |
| ▸ | POLA1 | P09884 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657522 | 0.92 | KCNH2 (0.63) | KCNH2POLA1F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6660047 | 0.92 | KCNH2 (0.58) | KCNH2POLA1RXFP1F2ALDH1A1 | |
| SCHEMBL6345199 | 0.91 | KCNH2 (0.52) | KCNH2POLA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6710929 | 0.91 | KCNH2 (0.75) | KCNH2POLA1F2 | |
| SCHEMBL6659286 | 0.89 | KCNH2 (0.67) | KCNH2POLA1F2 | |
| SCHEMBL6659712 | 0.88 | KCNH2 (0.65) | KCNH2POLA1F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6662076 | 0.88 | KCNH2 (0.67) | KCNH2POLA1F2 | |
| SCHEMBL6655999 | 0.88 | KCNH2 (0.58) | KCNH2POLA1F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6338143 | 0.86 | KCNH2 (0.82) | KCNH2POLA1 | |
| SCHEMBL6655837 | 0.84 | KCNH2 (0.60) | KCNH2POLA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421089-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | Pharmacia & Upjohn Company (US) | 2004-05-26 | — | — | EP | claimed |
| US-6620810-B2 | Treating a herpesvirus infection, atherosclerosis or restenosis | PHARMACIA & UPJOHN COMPANY | 2003-09-16 | — | — | US | claimed |
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | claimed |
| WO-2003020729-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| EP-1421089-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | Pharmacia & Upjohn Company (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6620810-B2 | Treating a herpesvirus infection, atherosclerosis or restenosis | PHARMACIA & UPJOHN COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | disclosed |
| WO-2003020729-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | IRF3, IRAK4, IFNAR1 | KCNH2 1293/4885POLA1 605/4885RXFP1 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.